ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Reverse Split

<< Previous

Bullboard Posts

Next >>

Comment by goldtechon May 25, 2021 1:36pm

128 Views

Post# 33260703

RE:RE:Reverse Split

No this is not a scare attempt and is something that needs to be addressed whether you like it or not. A reverse split needs shareholder approval and to accommodate a Nasdaq listing alone is not a good enough reason to put this to a vote. Your shareholdings are nothing compared to our NO VOTE.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports